LABORATORY RESEARCH Reduced Production of B-1–Specified Common Lymphoid Progenitors Results in Diminished Potential of Adult Marrow to Generate B-1 Cells To address the B-1B cell production controversy, investigators compared the efficiency with which hematopoietic stem cells and common lymphoid progenitors (CLPs) from neonates and adults generated B-1 cells in vivo and developed a clonal in vitro assay to quantify B-1 progenitor production from CLPs. [Proc Natl Acad Sci U S A] Arsenic Disulfide Synergizes with the Phosphoinositide 3-Kinase Inhibitor PI-103 to Eradicate Acute Myeloid Leukemia Stem Cells by Inducing Differentiation Investigators explored a novel combination approach to enhance the eradication of leukemia stem cells by arsenic in non- acute promyelocytic leukemia. [Carcinogenesis] Aryl Hydrocarbon Receptor Activation in Hematopoietic Stem/Progenitor Cells Alters Cell Function and Pathway-Specific Gene Modulation Reflecting Changes in Cellular Trafficking and Migration In this study, scientists tested the hypothesis that 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated phenotypic and functional changes of hematopoietic stem cells are a result of changes in gene expression that disrupt stem cell numbers and/or their migration. [Mol Pharmacol] Effects of Stem Cell Factor on Hypoxia-Inducible Factor 1 Alpha Accumulation in Human Acute Myeloid Leukemia and LAD2 Mast Cells Here researchers show that stem cell factor induces hypoxia-inducible factor 1α accumulation in THP-1 human myeloid leukemia cells but not in LAD2 mast cells. [PLoS One] CLINICAL RESEARCH Autologous Non-Myeloablative Hematopoietic Stem-Cell Transplantation Compared with Pulse Cyclophosphamide Once Per Month for Systemic Sclerosis (ASSIST): An Open-Label, Randomized Phase II Trial Investigators aimed to assess safety and efficacy of autologous non-myeloablative hematopoietic stem-cell transplantation in a Phase II trial compared with the standard of care, cyclophosphamide. [Lancet] Outcomes of a 1-Day Nonmyeloablative Salvage Regimen for Patients with Primary Graft Failure After Allogeneic Hematopoietic Cell Transplantation Scientists report the outcome of 11 patients with hematologic diseases (median age, 44; range, 25–67 years, seven males) who received a 1-day reduced-intensity preparative regimen given as a re-transplantation for primary graft failure. [Bone Marrow Transplant] Classifying Cytogenetics in Patients with AML in Complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study Researchers studied 821 adult patients reported to the CIBMTR who underwent hematopoietic cell transplantation for AML in first or second CR between 1999 and 2004. [Biol Blood Marrow Transplant] Outcomes of Hodgkin’s Lymphoma Patients with Relapse or Progression Following Autologous Hematopoietic Cell Transplantation In a multicenter retrospective study investigators evaluated 126 patients who relapsed/progressed after a median of 5 (1-132) months post 1st autologous hematopoietic cell transplantation. [Biol Blood Marrow Transplant] |